Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers

Moderna's stock rose 101% after the company announced that a personalized cancer vaccine developed with Merck reduced melanoma recurrence in a late-stage trial and met a secondary goal of preventing tumor spread to new areas. Estee Lauder's shares gained after the company reported fourth-quarter adjusted earnings per share and sales that exceeded consensus estimates, with fiscal 2027 guidance above Street expectations. La-Z-Boy's stock fell after the furniture maker's second-quarter sales forecast missed average analyst estimates.

Next story